Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy

被引:228
作者
Appelt, Ane L. [1 ,2 ]
Ploen, John [1 ]
Vogelius, Ivan R. [3 ]
Bentzen, Soren M. [4 ]
Jakobsen, Anders [1 ,2 ]
机构
[1] Vejle Hosp, Dept Oncol, DK-7100 Vejle, Denmark
[2] Univ So Denmark, Odense, Denmark
[3] Univ Copenhagen, Rigshosp, Dept Radiat Oncol, DK-1168 Copenhagen, Denmark
[4] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 85卷 / 01期
关键词
PHASE-III TRIAL; TUMOR-REGRESSION; NEOADJUVANT CHEMORADIOTHERAPY; CHEMOTHERAPY; RADIOTHERAPY; CARCINOMA; ESCALATION;
D O I
10.1016/j.ijrobp.2012.05.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Preoperative chemoradiation therapy (CRT) is part of the standard treatment of locally advanced rectal cancers. Tumor regression at the time of operation is desirable, but not much is known about the relationship between radiation dose and tumor regression. In the present study we estimated radiation dose-response curves for various grades of tumor regression after preoperative CRT. Methods and Materials: A total of 222 patients, treated with consistent chemotherapy and radiation therapy techniques, were considered for the analysis. Radiation therapy consisted of a combination of external-beam radiation therapy and brachytherapy. Response at the time of operation was evaluated from the histopathologic specimen and graded on a 5-point scale (TRG1-5). The probability of achieving complete, major, and partial response was analyzed by ordinal logistic regression, and the effect of including clinical parameters in the model was examined. The radiation dose-response relationship for a specific grade of histopathologic tumor regression was parameterized in terms of the dose required for 50% response, D-50,D-i, and the normalized dose-response gradient, gamma(50,i). Results: A highly significant dose-response relationship was found (P=.002). For complete response (TRG1), the dose-response parameters were D-50,D-TRG1 = 92.0 Gy (95% confidence interval [CI] 79.3-144.9 Gy), gamma(50,TRG1) = 0.982 (CI 0.533-1.429), and for major response (TRG1-2) D-50,D-TRG1&2 = 72.1 Gy (CI 65.3-94.0 Gy), gamma(50,TRG1&2) = 0.770 (CI 0.338-1.201). Tumor size and N category both had a significant effect on the dose-response relationships. Conclusions: This study demonstrated a significant dose-response relationship for tumor regression after preoperative CRT for locally advanced rectal cancer for tumor dose levels in the range of 50.4-70 Gy, which is higher than the dose range usually considered. (C) 2013 Elsevier Inc.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 23 条
[1]   Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial [J].
Aschele, Carlo ;
Cionini, Luca ;
Lonardi, Sara ;
Pinto, Carmine ;
Cordio, Stefano ;
Rosati, Gerardo ;
Artale, Salvatore ;
Tagliagambe, Angiolo ;
Ambrosini, Giovanni ;
Rosetti, Paola ;
Bonetti, Andrea ;
Negru, Maria Emanuela ;
Tronconi, Maria Chiara ;
Luppi, Gabriele ;
Silvano, Giovanni ;
Corsi, Domenico Cristiano ;
Bochicchio, Anna Maria ;
Chiaulon, Germana ;
Gallo, Maurizio ;
Boni, Luca .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) :2773-2780
[2]  
Bentzen SM, 1997, INT J RADIAT BIOL, V71, P531, DOI 10.1080/095530097143860
[3]   Chemotherapy with preoperative radiotherapy in rectal cancer [J].
Bosset, Jean-Francois ;
Collette, Laurence ;
Calais, Gilles ;
Mineur, Laurent ;
Maingon, Philippe ;
Radosevic-Jelic, Ljiljana ;
Daban, Alain ;
Bardet, Etienne ;
Beny, Alexander ;
Ollier, Jean-Claude .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) :1114-1123
[4]   Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy [J].
Bouzourene, H ;
Bosman, FT ;
Seelentag, W ;
Matter, M ;
Coucke, P .
CANCER, 2002, 94 (04) :1121-1130
[5]   Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: A phase II dose escalation study [J].
Chan, AKP ;
Wong, AO ;
Langevin, J ;
Jenken, D ;
Heine, J ;
Buie, D ;
Johnson, DRE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :843-856
[6]   Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:: Results of FFCD 9203 [J].
Gerard, Jean-Pierre ;
Conroy, Thierry ;
Bonnetain, Franck ;
Bouche, Olivier ;
Chapet, Olivier ;
Closon-Dejardin, Marie-Therese ;
Untereiner, Michel ;
Leduc, Bernard ;
Francois, Eric ;
Maurel, Jean ;
Seitz, Jean-Francois ;
Buecher, Bruno ;
Mackiewicz, Remy ;
Ducreux, Michel ;
Bedenne, Laurent .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4620-4625
[7]   Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 [J].
Gerard, Jean-Pierre ;
Azria, David ;
Gourgou-Bourgade, Sophie ;
Martel-Laffay, Isabelle ;
Hennequin, Christophe ;
Etienne, Pierre-Luc ;
Vendrely, Veronique ;
Francois, Eric ;
de La Roche, Guy ;
Bouche, Olivier ;
Mirabel, Xavier ;
Denis, Bernard ;
Mineur, Laurent ;
Berdah, Jean-Francois ;
Mahe, Marc Andre ;
Becouarn, Yves ;
Dupuis, Olivier ;
Lledo, Gerard ;
Montoto-Grillot, Christine ;
Conroy, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1638-1644
[8]   The importance of applicator design for intraluminal brachytherapy of rectal cancer [J].
Hansen, Johnny Witterseh ;
Jakobsen, Anders .
MEDICAL PHYSICS, 2006, 33 (09) :3220-3224
[9]   The ESTRO Breur Lecture 2010: Towards a tailored patient approach in rectal cancer [J].
Haustermans, Karin ;
Debucquoy, Annelies ;
Lambrecht, Maarten .
RADIOTHERAPY AND ONCOLOGY, 2011, 100 (01) :15-21
[10]   Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost [J].
Jakobsen, A ;
Mortensen, JP ;
Bisgaard, C ;
Lindebjerg, J ;
Hansen, JW ;
Rafaelsen, SR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (02) :461-465